期刊
NEUROSCIENCE
卷 279, 期 -, 页码 94-101出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuroscience.2014.08.036
关键词
Alzheimer's disease; amyloid; purinergic; hippocampus; memory
资金
- 973 program from the Ministry of Science and Technology of China [2013CB835100]
- National Natural Science Foundation of China [81100822]
- Ningbo Key Science and Technology Project [2011C51006]
- Ningbo Natural Science Foundation [2011A610064]
- Leading and top Talents Project of Ningbo City [ZX2012000399]
- K.C. Wong Magna Fund of Ningbo University
Deposits of amyloid-beta (A beta) protein are one of the hallmarks of Alzheimer's disease (AD). Numerous studies report that the A beta peptide, especially in the oligomeric form, causes memory decline and other cognitive deficits. However, there have been very few effective interventions for termination or even delay of AD progression. Brilliant Blue G (BBG), a safe triphenylmethane dye and P2X7 antagonist, has been reported to have protective effects on neuroinflammation, ischemia, spinal injury and neurodegenerative disorders. Here we report that systematic administration of BBG diminishes spatial memory impairment and cognitive deficits in a mouse AD model produced by injecting soluble AD peptide into the hippocampal CA1 region. In addition, we show that A beta-induced loss of filopodia and spine density in cultured hippocampal neurons was prevented by administration of BBG. We conclude that BBG prevents the learning and memory impairment and cognitive deficits induced by the toxicity of soluble A beta, and improves the development of dendritic spines in hippocampal neurons in an AD model mouse. Considering the safety and blood-brain-barrier (BBB)-permeability of BBG, our data suggest a potential for BBG as a new therapy for AD. (c) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据